Patient and sales growth from Aisu-liu (pirfenidone) being added to China's reimbursement system

A theme centered on the inclusion of アイスーリュイ (pirfenidone) in China’s new national medical insurance drug list, with the aim of increasing the number of patients receiving treatment, treatment persistence, stable supply and sales by reducing patients’ out-of-pocket costs.